These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38166764)

  • 21. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
    Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
    J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
    Vitale P; Zanaletti N; Famiglietti V; De Falco V; Cervantes A; Rosellò S; Fenocchio E; Milanesio M; Lombardi P; Ciardiello D; Martini G; Martinelli E; Ciardiello F; Troiani T; Napolitano S
    Clin Colorectal Cancer; 2021 Sep; 20(3):227-235. PubMed ID: 34226142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.
    Yan H; Liu J; Zhang Y; Chen S; Xu J; Gao D; Li H; Fang X; Wang Y; Wang H; Wang H
    J Gastrointest Oncol; 2024 Jun; 15(3):987-1001. PubMed ID: 38989408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.
    Xu D; Liu Y; Tang W; Xu L; Liu T; Jiang Y; Zhou S; Qin X; Li J; Zhao J; Ye L; Chang W; Xu J
    Front Oncol; 2022; 12():838870. PubMed ID: 35433423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
    Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
    Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
    Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
    Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
    Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
    Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M
    Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
    Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of raltitrexed plus S-1
    Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
    Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
    Min ST; Roohullah A; Tognela A; Jalali A; Lee M; Wong R; Shapiro J; Burge M; Yip D; Nott L; Zimet A; Lee B; Dean A; Steel S; Wong HL; Gibbs P; Lim SH
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e56-e63. PubMed ID: 33870631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
    Martínez-Lago N; Cameselle García S; Alonso de Castro B; Gómez-Randulfe Rodríguez MI; Carmona Campos M; González Villarroel P; Salgado Fernández M; De la Cámara Gómez JC; Romero Reinoso C; Cousillas Castiñeiras A; Méndez Méndez JC; Vidal Insua Y; Fernández-Montes A
    PLoS One; 2022; 17(6):e0269399. PubMed ID: 35657983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.